Merck & Co.’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended By CDC’s Advisory Committee On Immunization Practices For Females Aged 9-26 And Males Aged 9-21

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to include GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in the recommendations for use of HPV vaccines. GARDASIL 9 has been added to the routine recommendations for vaccination of 11- and 12- year-old females and males. The vaccination series can be started at age nine. Vaccination is also recommended for females aged 13 to 26 and for males aged 13 to 21 who have not been vaccinated previously or have not completed the 3-dose series. GARDASIL 9 is not approved by the U.S. Food and Drug Administration (FDA) for use in males 16 years of age and above.

Help employers find you! Check out all the jobs and post your resume.